Journal article
Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease
Abstract
Patients with end-stage kidney disease (ESKD) experience a high thrombotic risk but are also at increased risk of bleeding. There is an unmet need for safer antithrombotic therapy in patients with ESKD on hemodialysis. Factor XI (FXI) represents an attractive therapeutic target for anticoagulation because of the potential to mitigate the bleeding risks associated with currently approved anticoagulants, especially in patients at high risk of …
Authors
Ades M; Simard C; Vanassche T; Verhamme P; Eikelboom J; Mavrakanas TA
Journal
Seminars in Nephrology, Vol. 43, No. 6,
Publisher
Elsevier
Publication Date
November 2023
DOI
10.1016/j.semnephrol.2023.151484
ISSN
0270-9295